Guangsheng Nong – Trademark Portfolio
Entity Type: 01
Guangsheng Nong owns a portfolio of 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as BPZQX, BWPYP, MGXDV, DXVCPF, and NNPKGL. Of these, 7 are registered and 2 are pending. The portfolio spans 6 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 25 (Clothing). Headquartered in Wenshan.
Room 110, Weifeng Group, Jiuzhai Village Committee, Guichao Town, Funing County
Wenshan 663400 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangsheng Nong's trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Games and playthings; gymnastic and sporting articles; decorations for Christmas trees
Frequently Asked Questions
How many trademarks does Guangsheng Nong have?
Guangsheng Nong has 9 U.S. trademarks filed with the USPTO. Of these, 7 registered, 2 pending.
What trademark classes does Guangsheng Nong file in?
Guangsheng Nong files trademarks across 6 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 25 (Clothing), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 28 (Toys & Sporting Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Guangsheng Nong's most well-known trademarks?
Guangsheng Nong's registered trademark portfolio includes well-known marks such as BPZQX, BWPYP, MGXDV, DXVCPF, and NNPKGL. These are among 7 currently registered trademarks in the portfolio.
What is Guangsheng Nong's trademark registration success rate?
Guangsheng Nong has a 100% trademark registration rate, with 7 out of 7 resolved applications resulting in successful registration. Currently, 2 applications are pending review.